# Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

> **NCT06935409** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 117 (estimated)

## Conditions studied

- Osteosarcoma

## Interventions

- **DRUG:** HS-20093
- **DRUG:** Gemcitabine combined with docetaxel

## Key facts

- **NCT ID:** NCT06935409
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-25
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06935409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06935409, "Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06935409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*